{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:44:02Z","timestamp":1792122242100,"version":"4.4.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004901","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de Minas Gerais","doi-asserted-by":"publisher","award":["APQ01816-22"],"award-info":[{"award-number":["APQ01816-22"]}],"id":[{"id":"10.13039\/501100004901","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["300298\/2025-0"],"award-info":[{"award-number":["300298\/2025-0"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40261-026-01552-0","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T04:17:48Z","timestamp":1776745068000},"page":"641-653","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical Benefit of Multiple Myeloma Drugs at Regulatory Approval in Brazil, Europe, and the USA: A Retrospective Cohort Study (2003\u20132024)"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6269-8745","authenticated-orcid":false,"given":"Marina Alacoque","family":"Rodrigues","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7083-3188","authenticated-orcid":false,"given":"Cristiane Aparecida Menezes","family":"de P\u00e1dua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4639-7424","authenticated-orcid":false,"given":"Paula Lana","family":"de Miranda Drummond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4693-3113","authenticated-orcid":false,"given":"Pedro Henrique Carvalho","family":"de Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4610-393X","authenticated-orcid":false,"given":"J\u00e9ssica Soares","family":"Malta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0017-7338","authenticated-orcid":false,"given":"Adriano Max Moreira","family":"Reis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"1552_CR1","doi-asserted-by":"publisher","first-page":"e670","DOI":"10.1016\/S2352-3026(22)00165-X","volume":"9","author":"J Huang","year":"2022","unstructured":"Huang J, Chan SC, Lok V, et al. The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends. Lancet Haematol. 2022;9:e670\u20137. https:\/\/doi.org\/10.1016\/S2352-3026(22)00165-X.","journal-title":"Lancet Haematol."},{"key":"1552_CR2","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/ajh.25791","volume":"95","author":"SV Rajkumar","year":"2020","unstructured":"Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification, and management. Am J Hematol. 2020;95:548\u201367. https:\/\/doi.org\/10.1002\/ajh.25791.","journal-title":"Am J Hematol"},{"key":"1552_CR3","doi-asserted-by":"publisher","DOI":"10.7189\/jogh.14.04033","volume":"14","author":"J Geng","year":"2024","unstructured":"Geng J, Zhao J, Fan R, et al. Global, regional, and national burden, and quality of care of multiple myeloma, 1990\u20132019. J Glob Health. 2024;14:04033. https:\/\/doi.org\/10.7189\/jogh.14.04033.","journal-title":"J Glob Health"},{"key":"1552_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1490630","volume":"14","author":"B Huang","year":"2024","unstructured":"Huang B, Zhang H, Liu J, et al. The characteristics of patients with multiple myeloma surviving over 10 years. Front Oncol. 2024;14:1490630. https:\/\/doi.org\/10.3389\/fonc.2024.1490630.","journal-title":"Front Oncol"},{"key":"1552_CR5","doi-asserted-by":"publisher","first-page":"e374","DOI":"10.1016\/S1470-2045(24)00094-9","volume":"25","author":"Y Lin","year":"2024","unstructured":"Lin Y, Qiu L, Usmani S, et al. Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma. Lancet Oncol. 2024;25:e374\u201387. https:\/\/doi.org\/10.1016\/S1470-2045(24)00094-9.","journal-title":"Lancet Oncol"},{"key":"1552_CR6","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1111\/bcp.15141","volume":"88","author":"LT Bloem","year":"2022","unstructured":"Bloem LT, Bot RE, Mantel-Teeuwisse AK, et al. Pre-approval and post-approval availability of evidence and clinical benefit of conditionally approved cancer drugs in Europe. Br J Clin Pharmacol. 2022;88:2169\u201379. https:\/\/doi.org\/10.1111\/bcp.15141.","journal-title":"Br J Clin Pharmacol"},{"key":"1552_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m3434","volume":"371","author":"TJ Hwang","year":"2020","unstructured":"Hwang TJ, Ross JS, Vokinger KN, Kesselheim AS. Association between FDA and EMA expedited approval programs and therapeutic value of new medicines: retrospective cohort study. BMJ. 2020;371:m3434. https:\/\/doi.org\/10.1136\/bmj.m3434.","journal-title":"BMJ"},{"key":"1552_CR8","doi-asserted-by":"publisher","first-page":"4443","DOI":"10.3390\/curroncol31080332","volume":"31","author":"RB Barreto","year":"2024","unstructured":"Barreto RB, Izidoro AM, Miranda MHF. New oncologic drugs from 2008 to 2023\u2014differences in approval and access between the United States, Europe, and Brazil. Curr Oncol. 2024;31:4443\u201354. https:\/\/doi.org\/10.3390\/curroncol31080332.","journal-title":"Curr Oncol"},{"key":"1552_CR9","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1007\/s43441-022-00480-3","volume":"57","author":"P Franco","year":"2023","unstructured":"Franco P, Jain R, Rosenkrands-Lange E, Hey C, Koban MU. Regulatory pathways supporting expedited drug development and approval in ICH member countries. Ther Innov Regul Sci. 2023;57:484\u2013514. https:\/\/doi.org\/10.1007\/s43441-022-00480-3.","journal-title":"Ther Innov Regul Sci"},{"key":"1552_CR10","doi-asserted-by":"publisher","first-page":"5881","DOI":"10.1007\/s00277-024-05684-1","volume":"103","author":"MX Teixeira","year":"2024","unstructured":"Teixeira MX, Reis AMM, Drummond PLM, et al. Incidence and reasons for discontinuation of first-line therapy in patients with multiple myeloma: results from a historical cohort, Brazil 2009\u20132020. Ann Hematol. 2024;103:5881\u20139. https:\/\/doi.org\/10.1007\/s00277-024-05684-1.","journal-title":"Ann Hematol"},{"key":"1552_CR11","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1001\/jamainternmed.2015.5868","volume":"175","author":"C Kim","year":"2015","unstructured":"Kim C, Prasad V. Cancer drugs approved on the basis of a surrogate end point and subsequent overall survival: an analysis of 5 years of US Food and Drug Administration approvals. JAMA Intern Med. 2015;175:1992\u20134. https:\/\/doi.org\/10.1001\/jamainternmed.2015.5868.","journal-title":"JAMA Intern Med"},{"key":"1552_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j4530","volume":"359","author":"C Davis","year":"2017","unstructured":"Davis C, Naci H, Gurpinar E, et al. Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study. BMJ. 2017;359:j4530. https:\/\/doi.org\/10.1136\/bmj.j4530.","journal-title":"BMJ"},{"key":"1552_CR13","unstructured":"U.S. Food and Drug Administration. Drugs@FDA: FDA-Approved Drugs. In: FDA Database. 2024. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm. Accessed 20 Dec 2024."},{"key":"1552_CR14","unstructured":"European Medicines Agency. Medicines for human use. In: EMA Medicines Search. 2024. https:\/\/www.ema.europa.eu\/en\/medicines. Accessed 20 Dec 2024."},{"key":"1552_CR15","unstructured":"Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria. Consulta a registro de medicamentos. In: Sistemas Anvisa. 2024. https:\/\/www.gov.br\/anvisa\/pt-br\/sistemas\/consulta-a-registro-de-medicamentos. Accessed 20 Dec 2024."},{"key":"1552_CR16","unstructured":"U.S. Food and Drug Administration. Compilation of CDER New Molecular Entity (NME) drug and new biologic approvals. In: FDA Drug Approvals and Databases. 2024.https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals. Accessed 2 Feb 2024."},{"key":"1552_CR17","unstructured":"U.S. Food and Drug Administration. New Molecular Entity (NME) drug and new biologic approvals. In: FDA NDA and BLA Approvals. 2024. https:\/\/www.fda.gov\/drugs\/nda-and-bla-approvals\/new-molecular-entity-nme-drug-and-new-biologic-approvals. Accessed 2 Feb 2024."},{"key":"1552_CR18","unstructured":"European Medicines Agency. Committee for medicinal products for human use (CHMP). In: EMA Committees. 2024. https:\/\/www.ema.europa.eu\/en\/committees\/committee-medicinal-products-human-use-chmp. Accessed 20 Dec 2024."},{"key":"1552_CR19","unstructured":"Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria. Bul\u00e1rio eletr\u00f4nico. In: Sistemas Anvisa. 2024. https:\/\/www.gov.br\/anvisa\/pt-br\/sistemas\/bulario-eletronico. Accessed 20 Dec 2024."},{"key":"1552_CR20","unstructured":"U.S. Food and Drug Administration. Fast track, breakthrough therapy, accelerated approval, priority review. In: Learn About Drug and Device Approvals. 2018. https:\/\/www.fda.gov\/patients\/learn-about-drug-and-device-approvals\/fast-track-breakthrough-therapy-accelerated-approval-priority-review. Accessed 3 May 2025."},{"key":"1552_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-023-01639-x","author":"DT Michaeli","year":"2024","unstructured":"Michaeli DT, Michaeli T, Albers S, Boch T, Michaeli JC. Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy. Eur J Health Econ. 2024. https:\/\/doi.org\/10.1007\/s10198-023-01639-x.","journal-title":"Eur J Health Econ"},{"key":"1552_CR22","unstructured":"European Medicines Agency. PRIME: priority medicines. In: Research and development. 2025. https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/research-development\/prime-priority-medicines. Accessed 3 May 2025."},{"key":"1552_CR23","unstructured":"European Medicines Agency. Conditional marketing authorization. In: Marketing Authorization. 2025. https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/marketing-Authorization\/conditional-marketing-Authorization. Accessed 3 May 2025."},{"key":"1552_CR24","unstructured":"European Medicines Agency. Accelerated assessment. In: Marketing Authorization. 2025. https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/marketing-Authorization\/accelerated-assessment. Accessed 3 May 2025."},{"key":"1552_CR25","unstructured":"Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria. Resolu\u00e7\u00e3o da Diretoria Colegiada \u2013 RDC 205 de 28 de dezembro de 2017. In: Atos Normativos Anvisa. 2017. https:\/\/bvsms.saude.gov.br\/bvs\/saudelegis\/anvisa\/2017\/rdc0205_28_12_2017.pdf. Accessed 26 Apr 2025."},{"key":"1552_CR26","unstructured":"Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria. RDC n\u00ba 1001\/2025 - Disp\u00f5e sobre o enquadramento na categoria priorit\u00e1ria. In: Regulamenta\u00e7\u00e3o de Pesquisa Cl\u00ednica. 2025. https:\/\/www.gov.br\/anvisa\/pt-br\/assuntos\/medicamentos\/pesquisaclinica\/regulamentacao. Accessed 8 May 2025."},{"key":"1552_CR27","unstructured":"Comiss\u00e3o Nacional de Incorpora\u00e7\u00e3o de Tecnologias no Sistema \u00danico de Sa\u00fade. Recomenda\u00e7\u00f5es da Conitec. In: Avalia\u00e7\u00e3o de Tecnologias em Sa\u00fade. 2025. https:\/\/www.gov.br\/conitec\/pt-br\/assuntos\/avaliacao-de-tecnologias-em-saude\/recomendacoes-conitec. Accessed 8 May 2025."},{"issue":"8","key":"1552_CR28","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1093\/annonc\/mdv249","volume":"26","author":"NI Cherny","year":"2015","unstructured":"Cherny NI, Sullivan R, Dafni U, et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann Oncol. 2015;26(8):1547\u201373. https:\/\/doi.org\/10.1093\/annonc\/mdv249.","journal-title":"Ann Oncol"},{"key":"1552_CR29","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2019-000611","volume":"5","author":"B Kiesewetter","year":"2020","unstructured":"Kiesewetter B, Cherny NI, Boissel N, et al. EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies. ESMO Open. 2020;5:e000611. https:\/\/doi.org\/10.1136\/esmoopen-2019-000611.","journal-title":"ESMO Open"},{"key":"1552_CR30","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l5221","volume":"366","author":"H Naci","year":"2019","unstructured":"Naci H, Davis C, Savovi\u0107 J, et al. Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysis. BMJ. 2019;366:l5221. https:\/\/doi.org\/10.1136\/bmj.l5221.","journal-title":"BMJ"},{"key":"1552_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-077108","volume":"14","author":"L Ding","year":"2024","unstructured":"Ding L, Yuan X, Wang Y, et al. Application of the ESMO Magnitude of Clinical Benefit Scale to assess the clinical benefit of antibody drug conjugates in solid cancer. BMJ Open. 2024;14:e077108. https:\/\/doi.org\/10.1136\/bmjopen-2023-077108.","journal-title":"BMJ Open"},{"key":"1552_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2023.100506","volume":"22","author":"AM Ivama-Brummell","year":"2023","unstructured":"Ivama-Brummell AM, Marciniuk FL, Wagner AK, et al. Marketing authorization and pricing of FDA-approved cancer drugs in Brazil: a retrospective analysis. Lancet Reg Health Am. 2023;22:100506. https:\/\/doi.org\/10.1016\/j.lana.2023.100506.","journal-title":"Lancet Reg Health Am."},{"key":"1552_CR33","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1111\/bjh.18568","volume":"200","author":"T Etekal","year":"2023","unstructured":"Etekal T, Koehn K, Sborov DW, et al. Time-to-event surrogate end-points in multiple myeloma randomised trials from 2005 to 2019: a surrogacy analysis. Br J Haematol. 2023;200:587\u201394. https:\/\/doi.org\/10.1111\/bjh.18568.","journal-title":"Br J Haematol"},{"key":"1552_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01109-4","volume":"14","author":"C Pawlyn","year":"2024","unstructured":"Pawlyn C, Schjesvold FH, Cairns DA, et al. Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigm. Blood Cancer J. 2024;14:134. https:\/\/doi.org\/10.1038\/s41408-024-01109-4.","journal-title":"Blood Cancer J"},{"key":"1552_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcpo.2025.100588","volume":"45","author":"S Ranganathan","year":"2025","unstructured":"Ranganathan S, Prasad V. Minimal residual disease negative: a novel endpoint for accelerated approval; what providers should know. J Cancer Policy. 2025;45:100588. https:\/\/doi.org\/10.1016\/j.jcpo.2025.100588.","journal-title":"J Cancer Policy"},{"key":"1552_CR36","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1001\/jamainternmed.2020.2250","volume":"180","author":"T Hilal","year":"2020","unstructured":"Hilal T, Gonzalez-Velez M, Prasad V. Limitations in clinical trials leading to anticancer drug approvals by the US Food and Drug Administration. JAMA Intern Med. 2020;180:1108\u201315. https:\/\/doi.org\/10.1001\/jamainternmed.2020.2250.","journal-title":"JAMA Intern Med"},{"key":"1552_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcpo.2022.100364","volume":"34","author":"A Walia","year":"2022","unstructured":"Walia A, Haslam A, Prasad V. FDA validation of surrogate endpoints in oncology: 2005-2022. J Cancer Policy. 2022;34:100364. https:\/\/doi.org\/10.1016\/j.jcpo.2022.100364.","journal-title":"J Cancer Policy"},{"key":"1552_CR38","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1001\/jamaoncol.2022.5985","volume":"9","author":"S Agrawal","year":"2023","unstructured":"Agrawal S, Sung S, Chang SM, et al. Use of single-arm trials for US Food and Drug Administration drug approval in oncology, 2002\u20132021. JAMA Oncol. 2023;9:266\u201372. https:\/\/doi.org\/10.1001\/jamaoncol.2022.5985.","journal-title":"JAMA Oncol"},{"key":"1552_CR39","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l5221","volume":"366","author":"H Naci","year":"2019","unstructured":"Naci H, Davis C, Savovi\u0107 J, et al. Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014\u201316. BMJ. 2019;366:l5221. https:\/\/doi.org\/10.1136\/bmj.l5221.","journal-title":"BMJ"},{"key":"1552_CR40","unstructured":"European Medicines Agency. Reflection paper on establishing efficacy based on single-arm trials submitted as pivotal evidence in a marketing Authorization. In: EMA News. 2023. https:\/\/www.ema.europa.eu\/en\/news\/single-arm-trials-pivotal-evidence-Authorization-medicines-eu. Accessed 3 Jun 2025."},{"key":"1552_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01212-0","volume":"15","author":"P Mukhopadhyay","year":"2025","unstructured":"Mukhopadhyay P, Abdullah HA, Opalinska JB, et al. The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development. Blood Cancer J. 2025;15:15. https:\/\/doi.org\/10.1038\/s41408-025-01212-0.","journal-title":"Blood Cancer J"},{"key":"1552_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2022.101374","volume":"18","author":"T Olivier","year":"2022","unstructured":"Olivier T, Prasad V. The approval and withdrawal of melphalan flufenamide (melflufen): implications for the state of the FDA. Transl Oncol. 2022;18:101374. https:\/\/doi.org\/10.1016\/j.tranon.2022.101374.","journal-title":"Transl Oncol"},{"key":"1552_CR43","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1053\/j.seminoncol.2023.03.006","volume":"50","author":"D Pan","year":"2023","unstructured":"Pan D, Mouhieddine TH, Upadhyay R, et al. Outcomes with panobinostat in heavily pretreated multiple myeloma patients. Semin Oncol. 2023;50:40\u20138. https:\/\/doi.org\/10.1053\/j.seminoncol.2023.03.006.","journal-title":"Semin Oncol"},{"key":"1552_CR44","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s40164-024-00507-5","volume":"13","author":"J Pu","year":"2024","unstructured":"Pu J, Liu T, Wang X, et al. Exploring the role of histone deacetylase and histone deacetylase inhibitors in the context of multiple myeloma. Exp Hematol Oncol. 2024;13:45. https:\/\/doi.org\/10.1186\/s40164-024-00507-5.","journal-title":"Exp Hematol Oncol"},{"key":"1552_CR45","doi-asserted-by":"publisher","first-page":"5593","DOI":"10.1007\/s00277-024-05684-1","volume":"104","author":"H Ludwig","year":"2025","unstructured":"Ludwig H, Mai EK, H\u00f6gner M, et al. Optimizing the use of melflufen (melphalan flufenamide) in relapsed or refractory multiple myeloma: recommendations for clinical practice. Ann Hematol. 2025;104:5593\u2013603. https:\/\/doi.org\/10.1007\/s00277-024-05684-1.","journal-title":"Ann Hematol"},{"key":"1552_CR46","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/bcp.14130","volume":"86","author":"R Joppi","year":"2020","unstructured":"Joppi R, Bertele V, Vannini T, et al. Food and Drug Administration vs European Medicines Agency: review times and clinical evidence on novel drugs at the time of approval. Br J Clin Pharmacol. 2020;86:170\u20134. https:\/\/doi.org\/10.1111\/bcp.14130.","journal-title":"Br J Clin Pharmacol"},{"key":"1552_CR47","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1007\/s43441-020-00169-5","volume":"54","author":"P Patel","year":"2020","unstructured":"Patel P, Cerqueira DM, Santos GML, et al. A baseline analysis of regulatory review timelines for Anvisa: 2013-2016. Ther Innov Regul Sci. 2020;54:1428\u201335. https:\/\/doi.org\/10.1007\/s43441-020-00169-5.","journal-title":"Ther Innov Regul Sci"},{"key":"1552_CR48","doi-asserted-by":"publisher","first-page":"4443","DOI":"10.3390\/curroncol31080332","volume":"31","author":"RB Barreto","year":"2024","unstructured":"Barreto RB, Izidoro AM, Miranda MHF. New oncologic drugs from 2008 to 2023-differences in approval and access between the United States, Europe and Brazil. Curr Oncol. 2024;31:4443\u201354. https:\/\/doi.org\/10.3390\/curroncol31080332.","journal-title":"Curr Oncol"},{"key":"1552_CR49","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.vhri.2019.07.006","volume":"20","author":"LC Pereira","year":"2019","unstructured":"Pereira LC, Sturzenegger DVR, Ortiz J, et al. Challenges in the regulation of high-cost treatments: an overview from Brazil. Value Health Reg Issues. 2019;20:191\u20135. https:\/\/doi.org\/10.1016\/j.vhri.2019.07.006.","journal-title":"Value Health Reg Issues"},{"key":"1552_CR50","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1182\/bloodadvances.2024014123","volume":"9","author":"V Hungria","year":"2025","unstructured":"Hungria V, Gaiolla R, Galvez K, et al. Health care systems as determinants of outcomes in multiple myeloma: final results from the Latin American MYLACRE study. Blood Adv. 2025;9:1293\u2013302. https:\/\/doi.org\/10.1182\/bloodadvances.2024014123.","journal-title":"Blood Adv"},{"key":"1552_CR51","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1097\/CCO.0000000000001088","volume":"36","author":"H Martinez-Cordero","year":"2024","unstructured":"Martinez-Cordero H, Fuentes-Lacouture C, von Glasenapp A, et al. The 5T\u2019s of health disparities in multiple myeloma in Latin America. Curr Opin Oncol. 2024;36:610\u20134. https:\/\/doi.org\/10.1097\/CCO.0000000000001088.","journal-title":"Curr Opin Oncol"},{"key":"1552_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00980-5","volume":"13","author":"Y Yang","year":"2020","unstructured":"Yang Y, Li Y, Gu H, et al. Emerging agents and regimens for multiple myeloma. J Hematol Oncol. 2020;13:150. https:\/\/doi.org\/10.1186\/s13045-020-00980-5.","journal-title":"J Hematol Oncol"},{"key":"1552_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032645","volume":"24","author":"HN Abramson","year":"2023","unstructured":"Abramson HN. Recent advances in the applications of small molecules in the treatment of multiple myeloma. Int J Mol Sci. 2023;24:2645. https:\/\/doi.org\/10.3390\/ijms24032645.","journal-title":"Int J Mol Sci"},{"key":"1552_CR54","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/s41417-024-00750-2","volume":"31","author":"M Sheykhhasan","year":"2024","unstructured":"Sheykhhasan M, Ahmadieh-Yazdi A, Vicidomini R, et al. CAR T therapies in multiple myeloma: unleashing the future. Cancer Gene Ther. 2024;31:667\u201386. https:\/\/doi.org\/10.1038\/s41417-024-00750-2.","journal-title":"Cancer Gene Ther"},{"key":"1552_CR55","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1424925","volume":"15","author":"M Rees","year":"2024","unstructured":"Rees M, Abdallah N, Yohannan B, et al. Bispecific antibody targets and therapies in multiple myeloma. Front Immunol. 2024;15:1424925. https:\/\/doi.org\/10.3389\/fimmu.2024.1424925.","journal-title":"Front Immunol"},{"key":"1552_CR56","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15061819","volume":"15","author":"D Swan","year":"2023","unstructured":"Swan D, Murphy P, Glavey S, et al. Bispecific antibodies in multiple myeloma: opportunities to enhance efficacy and improve safety. Cancers (Basel). 2023;15:1819. https:\/\/doi.org\/10.3390\/cancers15061819.","journal-title":"Cancers (Basel)"},{"key":"1552_CR57","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.hoc.2023.12.013","volume":"38","author":"N Abdallah","year":"2024","unstructured":"Abdallah N, Kumar SK. New therapies on the horizon for relapsed refractory multiple myeloma. Hematol Oncol Clin North Am. 2024;38:511\u201332. https:\/\/doi.org\/10.1016\/j.hoc.2023.12.013.","journal-title":"Hematol Oncol Clin North Am"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01552-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-026-01552-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01552-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T14:48:27Z","timestamp":1779806907000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-026-01552-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":57,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1552"],"URL":"https:\/\/doi.org\/10.1007\/s40261-026-01552-0","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]},"assertion":[{"value":"14 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported by the Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de Minas Gerais [FAPEMIG (Grant Number APQ01816-22)] and by the Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico [CNPq (Grant Number 300298\/2025-0)]. The funders were not involved in study design, data acquisition, analysis, interpretation, or preparation of the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors have no conflict of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest Statement"}},{"value":"This study relied exclusively on publicly available data from regulatory agencies. In accordance with Brazilian national regulations (National Health Council [CNS] Resolution No. 510, of April 7, 2016, Article 1st), research utilizing publicly accessible information that does not directly involve human subjects, or identifiable personal data is automatically exempt from ethical review.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"No custom code or mathematical algorithms were used in the generation of this manuscript.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"The compiled dataset that supports the findings of this study is available from the corresponding author upon reasonable request.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability Statement"}},{"value":"M.A.R, A.M.M.R, C.A.M.P, P.L.M.D, J.S.M conceptualized and designed the study. M.A.R and P.H.C.S collected the raw data from the original sources. A.M.M.R and M.A.R performed the data analysis and verified the underlying data reported in the manuscript. M.A.R wrote the first draft of the manuscript. All authors revised the manuscript and provided important intellectual content. All authors had full access to all the data in the study and had final responsibility for the decision to submit for publication. All authors read and approved the final version and agreed to be accountable for the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}